MHRA clears inavolisib, offering new option for returning breast cancer
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'
The receipt of this order further strengthens the company's position in the global pharmaceutical market
The audit was completed with zero critical and zero major observations
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
Subscribe To Our Newsletter & Stay Updated